Clinical Trial Update: A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial comparing Upadacitinib to placebo and to Adalimumab in psoriatic arthritis patients with inadequate response to non-biologic DMARDs; resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriatic Arthritis

Drugs mentioned

• ADALIMUMAB (ADALIMUMAB-AATY)
• Upadacitinib (upadacitinib)

Snippet

Sponsor: AbbVie | Conditions: Psoriatic Arthritis | Phase 3 | Status: COMPLETED | Results posted: 2022-01-25